Adam L Green
Children's Oncology Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adam L Green as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:39 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05099003 · A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)National Cancer Institute (NCI) · active not recruiting · Malignant Glioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- COG NCTN Network Group Operations CenterU10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2014 to 2026Named on NCT05099003
Most cited trial papers
Clinical-trial papers with this author name in glioma, ranked by citations from NIH iCite, fetched 2026-11-12 10:39 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.Clin Cancer Res · 202269 citationsRCR 4.1
- Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial.Clin Cancer Res · 202514 citationsRCR 3.5